NCT04101383 - A Study to Compare Pharmacokinetics and Pharmacodynamics of RinGlar® to Lantus® in Type 1 Diabetes Mellitus Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 16, 2017

Primary Completion Date

February 16, 2018

Study Completion Date

February 16, 2018

Conditions

Clamp Study

Interventions

DRUG

RinGlar®

Single subcutaneous administration of RinGlar® in dose 0.6 Units/kg

DRUG

Lantus®

Single subcutaneous administration of Lantus® in dose 0.6 Units/kg

Trial Locations (2)

Endocrinology Research Centre, Moscow

Almazov National Medical Research Centre, Saint Petersburg